Susquehanna International Group, LLP Infla Rx N.V. Transaction History

Susquehanna International Group, LLP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.25 - $2.75 $25,156 - $55,343	-20,125 Reduced 54.26%	16,966 $27,000
Q3 2023 Nov 14, 2023	SELL	$2.66 - $4.33 $375,466 - $611,192	-141,153 Reduced 79.19%	37,091 $110,000
Q2 2023 Aug 11, 2023	BUY	$2.05 - $6.1 $145,855 - $434,008	71,149 Added 66.44%	178,244 $794,000
Q1 2023 May 16, 2023	BUY	$1.66 - $3.1 $130,434 - $243,582	78,575 Added 275.51%	107,095 $207,000
Q4 2022 Feb 14, 2023	SELL	$2.11 - $3.25 $41,478 - $63,888	-19,658 Reduced 40.8%	28,520 $88,000

Q3 2022 Nov 14, 2022	BUY	$1.32 - $3.14 $1,884 - $4,483	1,428 Added 3.05%	48,178 $127,000
Q2 2022 Aug 15, 2022	BUY	$0.78 - $1.9 $36,465 - $88,825	46,750 New	46,750 $68,000
Q1 2022 May 16, 2022	SELL	$1.83 - $4.48 $50,167 - $122,814	-27,414 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.35 - $5.58 $23,742 - $56,374	-10,103 Reduced 26.93%	27,414 $130,000
Q3 2021 Nov 15, 2021	BUY	$2.25 - $3.03 $8,669 - $11,674	3,853 Added 11.45%	37,517 $97,000
Q2 2021 Aug 11, 2021	SELL	$2.72 - $4.04 $70,195 - $104,260	-25,807 Reduced 43.39%	33,664 $100,000
Q1 2021 May 17, 2021	BUY	$3.62 - $6.34 $121,639 - $213,036	33,602 Added 129.89%	59,471 $232,000
Q4 2020 Feb 16, 2021	SELL	$3.82 - $5.32 $20,326 - $28,307	-5,321 Reduced 17.06%	25,869 $130,000
Q3 2020 Nov 16, 2020	SELL	$3.7 - $5.47 $102,771 - $151,934	-27,776 Reduced 47.11%	31,190 $133,000
Q2 2020 Aug 14, 2020	BUY	$4.59 - $8.96 $270,653 - $528,335	58,966 New	58,966 $271,000

13.8M

12.9K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $76.5M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.